[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]
Fırat University Medical Journal of Health Sciences
2020, Cilt 34, Sayı 3, Sayfa(lar) 209-214
[ Turkish ] [ Tam Metin ] [ PDF ]
Efficacy of Abatacept Therapy in Patients with Seronegative and Seropositive Rheumatoid Arthritis
Ahmet KARATAŞ1, Servet YOLBAŞ2 Nevzat GÖZEL3, Rabia PİŞKİN SAĞIR1, Mustafa GÜR1, Süleyman Serdar KOCA1
1Fırat Üniversitesi, Tıp Fakültesi, Romatoloji Bilim Dalı, Elazığ, TÜRKİYE
2İnönü Üniversitesi, Tıp Fakültesi, Romatoloji Bilim Dalı, Malatya, TÜRKİYE
3Fırat Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Elazığ, TÜRKİYE
Keywords: Abatacept, rheumatoid arthritis, seropositive, seronegative

Objective: The aim of this study was to compare the abatacept treatment in terms of effectiveness in patients with seronegative and seropositive rheumatoid arthritis (RA).

Materials and Methods: Patients with RA who received abatacept treatment at Firat University Department of Rheumatology between 2014 and 2017, diagnosed according to the 2010 American Rheumatology Association criteria, were included in the study. Those with RF and/or anti-CCP auto-antibody positivity were grouped as seropositive RA, those with RF and/or anti-CCP auto-antibody negativity were grouped as seronegative RA. DAS 28-CRP, CDAI, HAQ and VAS scores, and laboratory data were evaluated, retrospectively.

Results: 37.1%(n=13) RF negativity and 62.9%(n=22) RF positivity were found in patients using abatacept. In patients, anti-CCP was negative in 34.2% (n=12), and anti-CCP was positive in 65.8% (n=23) The total number of patients who continued with abatacept treatment was 57.1% (n=20). While the abatacept retention rate was 59.1% in RF positive patients, this rate was 53.8% in RF negative patients (P=0.762). While the abatacept retention rate was 70% in anti-CCP positive patients, this rate was 50% in anti-CCP negative patients (P=0.284). The effect of seropositivity on the abatacept retention rate of treatment was not statistically significant. There was no statistical difference between the two groups in terms of DAS28-CRP, CDAI, VAS-pain, VAS-global, VAS-physician, and HAQ scores.

Conclusion: In our study, the effectiveness of abatacept therapy was found to be similar in seropositive and seronegative RA patients.


[ Turkish ] [ Tam Metin ] [ PDF ]
[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]